Enemies of Weed Legalization Are Already Raising Money To Challenge Federal Rescheduling Effort
Last week, the Drug Enforcement Administration (DEA) shared that marijuana would be rescheduled from a Schedule I, meaning that the plant was […]
Category: Drug Enforcement Administration
DEA Re-Hires Agent Who Was Fired for Taking CBD
The Department of Justice has rescinded a DEA decision to fire a special agent who was let go due to a positive […]
DEA confirms it is reviewing marijuana rescheduling recommendation
The U.S. Drug Enforcement Administration is currently “conducting its review” of an earlier recommendation that the agency reschedule marijuana, a DEA official […]
Unique cannabinoid delta-8 divides cannabis extraction industry
A rare cannabinoid that mimics the effects of delta-9 THC but can easily be produced from CBD is grabbing headlines and delivering […]
US House passes bill to expedite, expand medical cannabis research
The U.S. House of Representatives on Wednesday passed a groundbreaking bill to reduce barriers and expand scientific research into medical cannabis, a […]
DEA asks court to toss marijuana rescheduling appeal
The U.S. Drug Enforcement Administration reiterated that a lawsuit challenging marijuana’s classification as a Schedule 1 drug under the federal Controlled Substances […]
How GW Pharma Won CBD
As of this writing, the United States Food and Drug Administration (FDA) has approved GW Pharma’s CBD drug Epidiolex for treating profound […]
The DEA’s Interim Final Rule and its Impact on the Industrial Hemp Industry
On August 20, 2020, the Drug Enforcement Administration (DEA) published an Interim Final Rule on industrial hemp and hemp derivatives (the interim […]
CBD Industry Caught Between Regulators & Law Enforcement
The consumer-facing CBD industry operates in a regulatory gray zone even as it grows in prominence. Illegal to market as an unapproved […]
Court refuses to reject suit challenging marijuana’s listing as Schedule 1 drug
A lawsuit challenging marijuana’s federal classification as a Schedule 1 drug under the Controlled Substances Act remains alive after a federal appeals […]